NASDAQ:ACER - Acer Therapeutics Stock Price, Forecast & News

Acer Therapeutics' stock was trading at $3.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ACER stock has decreased by 45.3% and is now trading at $1.85. View which stocks have been mosted impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Acer Therapeutics.

Acer Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Acer Therapeutics.

Acer Therapeutics Inc (NASDAQ:ACER) announced its earnings results on Wednesday, March, 18th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.03. View Acer Therapeutics' earnings history.

5 brokerages have issued 1 year price targets for Acer Therapeutics' stock. Their forecasts range from $9.00 to $48.00. On average, they expect Acer Therapeutics' stock price to reach $22.33 in the next twelve months. This suggests a possible upside of 1,107.2% from the stock's current price. View analysts' price targets for Acer Therapeutics.

Media coverage about ACER stock has been trending extremely negative this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Acer Therapeutics earned a daily sentiment score of -4.0 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutAcer Therapeutics.

Some companies that are related to Acer Therapeutics include Genprex (GNPX), Xeris Pharmaceuticals (XERS), Clearside Biomedical (CLSD), Immunic (IMUX), Aptorum Group (APM), Monopar Therapeutics (MNPR), Aravive (ARAV), Adamas Pharmaceuticals (ADMS), SUMMIT THERAPEU/S (SMMT), Menlo Therapeutics (MNLO), Galmed Pharmaceuticals (GLMD), SCYNEXIS (SCYX), Vaccinex (VCNX), Catabasis Pharmaceuticals (CATB) and CV Sciences (CVSI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Sarepta Therapeutics (SRPT), Amarin (AMRN), Advanced Micro Devices (AMD), Novavax (NVAX), NVIDIA (NVDA), Synergy Pharmaceuticals (SGYP), NovaBay Pharmaceuticals (NBY), Anavex Life Sciences (AVXL), Arena Pharmaceuticals (ARNA) and Exelixis (EXEL).

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

Acer Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (1.10%), Barclays PLC (0.97%), J. Goldman & Co LP (0.73%), Goldman Sachs Group Inc. (0.51%), Bank of Montreal Can (0.14%) and CWS Financial Advisors LLC (0.10%). Company insiders that own Acer Therapeutics stock include Life Science Ventures Vii Tvm and Steve Aselage. View institutional ownership trends for Acer Therapeutics.

ACER stock was sold by a variety of institutional investors in the last quarter, including J. Goldman & Co LP, Goldman Sachs Group Inc., State Street Corp, and Bank of Montreal Can. View insider buying and selling activity for Acer Therapeutics.

ACER stock was purchased by a variety of institutional investors in the last quarter, including CWS Financial Advisors LLC, UBS Group AG, and Barclays PLC. Company insiders that have bought Acer Therapeutics stock in the last two years include Life Science Ventures Vii Tvm, and Steve Aselage. View insider buying and selling activity for Acer Therapeutics.

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ACER stock can currently be purchased for approximately $1.85.

Acer Therapeutics has a market capitalization of $18.69 million. The biopharmaceutical company earns $-29,420,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. Acer Therapeutics employs 23 workers across the globe. View additional information about Acer Therapeutics.

The official website for Acer Therapeutics is http://www.acertx.com/.

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]